B.C.-based psychedelic drug developer applies to go public in the U.S.

Clearmind Medicine's lead drug candidate is MEAI, a novel psychedelic molecule that could combat alcoholism and other disorders, like binge eating

Related Keywords

Canada ,Toronto ,Ontario ,Israel ,Winnipeg ,Manitoba ,Canadian ,Johnh Krystal ,Gal Yadid ,Adi Zuloff Shani ,Postmedia Network Inc ,Canadian Securities Exchange ,Bar Ilan University In Ramat Gan ,Gonda Multidisciplinary Brain Research Center ,Nasdaq ,Clearmind Medicine ,Psychiatry Department ,Yale University ,Scientific Advisory Board ,Professor Gal Yadid ,Bar Ilan University ,Ramat Gan ,Weekend Dispensary ,Postmedia Network ,Street East ,